AZ-PFKFB3-67

• Description:

  AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1, respectively. AZ-PFKFB3-67 reduces MCL-1. AZ-PFKFB3-67 has neuroprotective activity[1][2][3].

• UNSPSC:

  12352005

• Target:

  Bcl-2 Family; Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/az-pfkfb3-67.html

• Purity:

  97.03

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1NCCC1)NC2=CC=C(OC3=CC4=C(N(CC5=C(C)ON=C5C)C=C4C#N)C=C3)C=C2

• Molecular Formula:

  C26H25N5O3

• Molecular Weight:

  455.51

• References & Citations:

  [1]Boyd S, et al. Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. J Med Chem. 2015;58 (8) :3611-3625.|[2]Sneyers F, et al. Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing MCL-1-addicted cancer cells. Cell Death Dis. 2023 Sep 8;14 (9) :600. |[3]Madai S, et al. Activation of the hypoxia-inducible factor pathway protects against acute ischemic stroke by reprogramming central carbon metabolism. Theranostics. 2024 Apr 29;14 (7) :2856-2880.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1704741-11-6]